MLYCD: Enzyme Involved in Malonyl-CoA Cycle and Potential Drug Target

Target Name: MLYCD

NCBI ID: G23417

MLYCD

MLYCD: Enzyme Involved in Malonyl-CoA Cycle and Potential Drug Target

MLYCD (Malonyl-CoA Decarboxylase) is a enzyme involved in the metabolism of malonyl-CoA, a crucial molecule in the citric acid cycle (also known as the Krebs cycle or TCA cycle), which is a central metabolism pathway in eukaryotic cells. Malonyl-CoA is a key intermediate step in the citric acid cycle, and its metabolism is regulated by several enzymes, including MLYCD.

The citric acid cycle is a highly conserved biochemical pathway that is essential for the production of energy in the form of ATP from the food we consume. The pathway involves the breakdown of glucose and fatty acids into smaller molecules, such as carbon dioxide, water, and ATP, which are then used to synthesize the components of the cell. The malonyl-CoA cycle is a critical part of this pathway, as it is the site where carbon dioxide from the food is converted into malonyl-CoA, which is then used to produce energy.

MLYCD is a protein that is expressed in most eukaryotic cells and is involved in the malonyl-CoA cycle. It is a member of the superfamily of CoA-binding proteins (SBPs), which are a group of enzymes that are involved in the metabolism of CoA, a molecule that is derived from the 2-carbon unit of fatty acids. SBPs are characterized by a specific domain that allows them to bind to CoA, as well as a catalytic active site that is involved in the chemical reaction that occurs when CoA is bound to the protein.

One of the key functions of MLYCD is its role in the malonyl-CoA cycle. It is the enzyme that catalyzes the conversion of carbon dioxide and malonyl-CoA to produce ethyl-CoA and carbon dioxide. This reaction is critical for the production of ATP from the food we consume, as the carbon dioxide produced during this reaction is then used to synthesize ATP through the citric acid cycle.

In addition to its role in the malonyl-CoA cycle, MLYCD is also involved in the regulation of other cellular processes. For example, it has been shown to be involved in the metabolism of lipids, including fats and oils, and has been shown to play a role in the production of fatty acids. It is also involved in the production of aromatic amino acids, which are important for the structure and function of many proteins in the cell.

MLYCD is a potential drug target for several reasons. Firstly, it is a key enzyme involved in the malonyl-CoA cycle, which is a critical pathway for the production of ATP and energy in the cell. Secondly, it is a conserved protein that is found in most eukaryotic cells, which makes it a potential target for small molecules that can inhibit its activity. Finally, its function in the malonyl-CoA cycle is well understood, which makes it a potential target for drug development.

In conclusion, MLYCD is a protein that is involved in the malonyl-CoA cycle, which is a critical pathway for the production of ATP and energy in the cell. It is a member of the SBP family and has been shown to play a role in the regulation of other cellular processes. As a result, MLYCD is a potential drug target for several reasons, including its involvement in the malonyl-CoA cycle and its conserved nature. Further research is needed to fully understand its function and potential as a drug target.

Protein Name: Malonyl-CoA Decarboxylase

Functions: Catalyzes the conversion of malonyl-CoA to acetyl-CoA. In the fatty acid biosynthesis MCD selectively removes malonyl-CoA and thus assures that methyl-malonyl-CoA is the only chain elongating substrate for fatty acid synthase and that fatty acids with multiple methyl side chains are produced. In peroxisomes it may be involved in degrading intraperoxisomal malonyl-CoA, which is generated by the peroxisomal beta-oxidation of odd chain-length dicarboxylic fatty acids. Plays a role in the metabolic balance between glucose and lipid oxidation in muscle independent of alterations in insulin signaling. May play a role in controlling the extent of ischemic injury by promoting glucose oxidation

The "MLYCD Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MLYCD comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets